Vitiligo Treatment Market research report: information By Type (Segmental Vitiligo, Non-Segmental vitiligo), By Treatment Type (Therapy, [Depigmentation, Light], Surgery [Skin grafting, Blister grafting, and Micro-pigmentation], and Medication, [Topical Corticosteroids, Immunosuppressive]) By End-user (Hospitals, Ambulatory, Clinics Others), and By Region (North America, Europe, Asia-pacific and Rest of the World) - Forecast till 2030

Vitiligo Treatment Market Overview:

The Vitiligo Treatment Market size was valued USD 1.33 billion in 2021 and is projected to reach USD 2.26 billion by 2030 at 6.20% CAGR during the forecast period (2022 - 2030)

Vitiligo is a chronic dermatological disorder characterized by skin depigmentation caused by the malfunctioning or death of the skin's pigment-producing cells known as melanocytes. As a result, well-defined white patches appear on the skin. The conditions persist, causing larger areas of skin to lose pigment. Treatment may improve skin appearance but does not cure the disease. The key factors that drive the global vitiligo treatment market are the growing importance of aesthetic appeal and awareness and the increasing prevalence of vitiligo cases. the development of technology proposing therapies for treating different complications caused by the disorder, and the prevalence of investments by government bodies in healthcare infrastructure accelerates the market growth. However, the lack of trained professionals is anticipated to hamper the market growth.

COVID-19 Analysis

The COVID-19 pandemic majorly affected the vitiligo treatment procedures as vitiligo condition does not fall in urgent and emergency cases and was considered elective procedures. During the starting of the pandemic, this led to sudden restrictions on ongoing medical procedures and significantly impacted treatment sessions. Several patients also had to shift to different medications suitable for home use for a time being.

The lockdown and restrictions due to COVID-19 in several regions had resulted in a negative impact on the market supply chain of the vitiligo treatment. As a result of the pandemic, several countries implemented import and export restrictions, which adversely affected the market supply chain of the vitiligo treatment.

Market Dynamics

Market Drivers

• Growing importance of the aesthetic appeal and awareness

In recent years, there is a significant rise in beauty consciousness among consumers owing to the growing awareness among consumers about different aesthetics treatments, increasing per capita income, and adoption of digital platforms. According to the International Society of Aesthetic Plastic Surgery (ISAPS), there was a 27.3% growth in worldwide total non-surgical procedures between 2015 and 2019. In addition, according to the American Society of Plastic Surgeons (ASPS), the number of minimally invasive aesthetic procedures witnessed about a 200% increase during 2000-2017. Moreover, about 15.9 million minimally invasive cosmetic procedures were performed in 2018, which was a 2% rise in comparison to 2017. Thus, the increasing geriatric population also drives the demand for minimally invasive cosmetic procedures.

• Increasing prevalence of vitiligo

Market Restraints

• Lack of trained professionals

A lack of trained dermatologists leads to several hurdles such as incorrect diagnosis, longer wait times, overworked doctors, and inefficient treatments. For instance, according to the American Academy of Dermatology (AAD), the total number of dermatologists in the US had decreased from 19,957 professionals in 2019 to 18,898 professionals in 2020. Hence, the lack of such capable professionals to efficient diagnose and provide treatment for vitiligo is restraining market growth, however, historically the number of dermatologists has increased, and the impact of the restraint is expected to be moderate.

Market Opportunities

• Rising number of clinical trials

Research & development and clinical trials are imperative for market innovation and growth. Extensive R&D leads to the development of more effective and superior products that aid in better patient treatment, supplementing the market growth. Moreover, there are several products in the pipelines and in clinical trials that are expected to significantly augment the market growth if they get approval from the concerned regulatory entities. With several clinical trials still in process, there were no medications approved to cure vitiligo until July 2022. In July 2022, FDA approved the first-ever re-pigmentation therapy for non-segmental vitiligo called 1.5% ruxolitinib (Opzelura) cream for patients of age 12 years and older. Hence, such efforts taken by players to develop novel products are expected to significantly drive market growth in the forecast period upon product approval.

Value Chain Analysis

The vitiligo treatment market is growing at a significant rate and is expected to continue growing at the same rate in the near future. This is due to the growing importance of aesthetic appeal and technological advancements in treatment methods. The market value chain analysis for the vitiligo treatment comprises four major components that start with the research and product development (R&D), followed by the manufacturing of the products, distribution & sales, and end with post-sales monitoring.

Segment Overview

By Type

• Segmental vitiligo

Segmental vitiligo, also known as unilateral or localized vitiligo, is a less frequent condition that manifests asymmetrically on a person's body that causes the skin on one part of the body to become unpigmented or lose its color. Every three in ten children who already have vitiligo are affected by this disorder, which is more prevalent in children. Moreover, a person with vitiligo develops photosensitivity to the sun's UV rays, making their skin more vulnerable to sunburn or discomfort. Currently, there is no cure for vitiligo.

• Non-segmental vitiligo

Non-segmental vitiligo, the most common type, causes skin patches to appear all over the body when the skin color begins to go. When white patches on a person's body are symmetrical rather than non-symmetrical, non-segmental vitiligo is most likely present. This vitiligo affects 0.5% to 2% of the population globally, and 90% of the time it is non-segmental. Additionally, treatments for non-segmental vitiligo can vary significantly based on the patient's preferences and the severity of their condition.

By Treatment Type

• Therapy

There is no particular method of treating vitiligo, but with early detection and careful evaluation, the condition of vitiligo can be improved through personalized therapy options. The therapy segment is further bifurcated into depigmentation and light. Depigmentation therapy is a workable alternative therapy for patients with severe vitiligo. It is appropriate for all skin types. Furthermore, light therapy appears to be one of the most successful vitiligo treatments, according to a growing body of studies. It has been shown that narrow-band Ultraviolet B (UVB) phototherapy can slow or stop the progression of active vitiligo.

• Surgery

Surgery is a very good alternative when treating stable but challenging-to-treat disorders. Surgery can be used to treat segmental or localized vitiligo that only affects a limited area. Numerous patients all over the world have hope due to the creation of new methods and improvements to cell and tissue transplantation as a therapy option. Some patients with stable illnesses may be candidates for surgery if light treatment and medicines have failed. The surgery segment is further bifurcated into skin grafting, blister grafting, and micro-pigmentation.

• Medication

There are a few medications that are often used off-label for vitiligo treatment such as prostaglandins, tacrolimus, methoxsalen, abatacept, fluorouracil, among others. Corticosteroids are a type of prescription medication approved by the US FDA to treat inflammation. Topical corticosteroids are commonly used as a first-line treatment for adults and children with localized vitiligo. Hydrocortisone, clobetasol propionate, betamethasone valerate, diflucortolone valerate, triamcinolone acetonide, methylprednisolone, fluticasone, and mometasone are the most commonly used topical corticosteroids for vitiligo. Additionally, immunosuppressive medicines are used to treat autoimmune, inflammatory, and allergic illnesses by lowering the body's immunological response. Immune system-suppressing medications are used to control the progression of vitiligo.

By End-User

• Hospitals

Hospitals are usually the primary points for diagnosis, treatment, and rehabilitation of individuals suffering from skin diseases such as vitiligo. Government and private hospitals are included in the hospital sector. hospitals are using therapies and surgeries to treat and diagnose vitiligo disease. Furthermore, the growing awareness and increasing efficiency of medical services are projected to drive the growth of this segment during the forecast period.

• Ambulatory Clinics

Modern healthcare facilities known as Ambulatory Surgery Centers (ASCs) are devoted to providing same-day surgical care, including diagnostic and preventive procedures. Ambulatory care is care provided by healthcare professionals in outpatient settings. Hence, these settings include medical offices and clinics, ambulatory surgery centers, hospital outpatient departments, and dialysis centers.

• Others

Other end users of the global vitiligo treatment market include aesthetic clinics, and home care settings. A healthcare facility known as an aesthetics clinic is primarily dedicated to the treatment of outpatients. The main focus of an aesthetic skin care clinic is anti-aging care, though they may also provide treatments for vitiligo and other skin conditions. In addition, products for home care settings include a few topical products and devices to treat vitiligo.

Regional Analysis

Global: Vitiligo Treatment Market SHARE (%), BY Region, 2021Sources: MRFR Analysis

North America

North America dominated the global vitiligo treatment market in 2021. This is due to the increasing technological advancement with regard to vitiligo treatment, and the presence of a large number of market players in the region. Moreover, the presence of reimbursement activities and the growing importance of aesthetic appeal also contribute to regional market growth.

Europe

The vitiligo treatment market in Europe is being driven by the growing prevalence of vitiligo amongst individuals, changing lifestyles, increasing population attentiveness, availability of effective treatments, and the increasing number of clinical trials.

According to the article published in the Journal of the European Academy of Dermatology and Venereology (JEADV), the online-population-based survey demonstrated that the prevalence of vitiligo was 1.3% in Europe. Moreover, technological advancements in vitiligo treatment methods are being adopted in the region due to the number of people suffering. A strong R&D pipeline and positive results of clinical studies are further anticipated to drive the market of vitiligo treatment in the forthcoming years.

Asia-Pacific

The vitiligo treatment market in Asia-Pacific is being driven by an increase in the number of research and development activities and growing demand for advanced vitiligo treatment options. For instance, according to the Indian Dermatology Online Journal (IDOJ), a cross-sectional study was conducted among 200 patients with vitiligo, the study states that 16.5% of individuals had segmental vitiligo, while 83.5% had non-segmental vitiligo. Moreover, the rise in the number of initiatives undertaken by various public and private organizations in the form of acquisitions, collaborations, regulatory approvals, and investments in this region is aiding the market growth

Rest of the World   

The Rest of the World comprises the Middle East, Africa, and Latin America. The rest of the world accounted for the lowest market share of vitiligo treatment. For instance, according to the article published by the National Center for Biotechnology Information (NCBI) in January 2021, between 1.49% to 3.55% of Saudi Arabia’s population was suffering from vitiligo, of which more than half showed non-segmental vitiligo symptoms. Therefore, the growing prevalence of vitiligo due to genetic factors, increasing focus on treatment, and social support are significantly contributing to the vitiligo treatment market growth in the rest of the world region.

Competitive Landscape

The global vitiligo treatment market is distinguished by the presence of numerous global, regional, and local players catering to the increasing awareness associated with vitiligo disease, the subsequent need for advanced and effective treatment, increasing research funding, and collaborations. The market is becoming more profitable as a result of the increased use of cutting-edge medical technologies and ongoing company development to meet consumer demand. For instance, in July 2022, Incyte Corporation (US) received US Food and Drug Administration approval for the use of OPZELURA (ruxolitinib) cream to treat nonsegmental vitiligo. Therefore, the market is moderately fragmented due to rising competition, product launches, increased collaborative partnerships, and other strategic decisions to achieve operational efficiency.

List of companies with HQ

• Incyte (US)


• Koninklijke Philips N.V. (Netherlands)


• Bausch Health Companies Inc.(Canada)


• Reddy's Laboratories Ltd. (India)


• STRATA Skin Sciences(US)


• Clinuvel Pharmaceuticals Ltd (Australia)


• Roivant Sciences Ltd. (Switzerland)


• ISSAR Pharmaceuticals Pvt. Ltd.(India)


• Kernel Medical Equipment Co., LTD. (China)


• LightSource (US)

Recent Developments

• In July 2022, Incyte Corporation(US) received US Food and Drug Administration Approval for the OPZELURA (ruxolitinib) cream to treat nonsegmental vitiligo.


• In February 2022, STRATA Skin Sciences (US) launched XTRAC Momentum 1.0 in the US. This laser equipment is developed to treat adult and pediatric patients with vitiligo.


• In August 2021, STRATA Skin Sciences (US) acquired Ra Medical (US), which specializes in developing vitiligo phototherapy equipment. Furthermore, the acquisition assists STRATA in expanding throughout the US.

Report Overview

The study covers the existing short-term and long-term market effects. It helps decision-makers to draught short-term and long-term business plans by region. The report covers major regions in North America, Europe, Asia Pacific, and the Rest of the World. The report analyzes market drivers, restraints, opportunities, challenges, Porter's five forces, the value chain, and the impact of COVID-19 on the market.

Study Objectives

• To provide a comprehensive analysis of the global vitiligo treatment market and its sub-segments, thereby providing a detailed structure of the industry


• To provide detailed insights into factors driving and restraining the growth of the global market of vitiligo treatment


• To estimate the market size of the vitiligo treatment where 2018 to 2019 would be the historical period, 2021 shall be the base year, and 2022 to 2030 will be the forecast period for the study


• To provide strategic profiling of key companies (manufacturers and distributors) present across the countries, and comprehensively analyze their competitiveness/competitive landscape in this market


• To provide a value chain analysis for the global vitiligo treatment market.

Market Segmentation:

Global Vitiligo Treatment Market, By Type

• Segmental vitiligo


• Non-segmental vitiligo

Global Vitiligo Treatment Market, By Treatment Type

• 
  Therapy
  
  
  
  • Depigmentation
  
  
  • Light
  
  
  
  


• 
  Surgery
  
  
  
  • Skin grafting
  
  
  • Blister grafting
  
  
  • Micro-pigmentation
  
  
  
  


• 
  Medication
  
  
  
  • Topical Corticosteroids
  
  
  • Immunosuppressive
  
  
  
  

Global Vitiligo Treatment Market, By End-user

• Hospitals


• Ambulatory Clinics


• Others

Global Vitiligo Treatment Market, By Region

• 
  North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• 
  Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• 
  Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  


• 
  Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America
  
  
  
  

Intended audience:

• Healthcare Institutions


• Product developers


• Manufacturers/Distributors


• Research institutes


• Dermatologists